Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience
This study found that preoperative systemic therapy patterns are strongly associated with post-operative survival in metastatic long-bone disease: targeted therapy alone correlates with improved survival whereas preoperative use of chemotherapy-alone or combined with targeted agents-was associated with worse survival. These findings support incorporating contemporary treatment exposure into prognostic models and suggest that model recalibration to the immunotherapy era may be warranted.
Authors
- Kevin A. Raskin
- Joris R.H Hendriks (ORCID: https://orcid.org/0009-0003-2005-8269)
- Erik T. Newman
- Jens P. te Velde (ORCID: https://orcid.org/0009-0001-4872-1128)
- Olivier Q. Groot
- Michelle R Shimizu
- Paul C. Jutte
- Joseph H. Schwab
- Tom M. de Groot
- Job N. Doornberg
Institutions
- Cedars-Sinai Medical Center (US)
- University Medical Center Groningen (NL)
- Loyola University Chicago (US)
- Flinders Medical Centre (AU)
- Massachusetts General Hospital (US)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Journal of bone oncology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1016/j.jbo.2026.100751
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00